AlphaVax, Inc. has received notification from the National Institute of Allergies and Infectious Diseases (NIAID), one of the granting institutes of the National Institutes of Health (NIH), that it has been awarded a second grant to continue development of a smallpox vaccine based on AlphaVax's proprietary vector platform.

NIAID grant will support additional studies in rodents and non-human primates to further characterize the high-level protection observed previously in these species. Work completed during the first grant period demonstrated that AlphaVax's smallpox vaccine, which expresses four, highly conserved poxvirus proteins, could provide humoral responses comparable to those obtained with a licensed vaccine. Furthermore, the AlphaVax vaccine protected mice against vaccinia virus challenge and non-human primates against a lethal challenge with monkeypox virus. The details of this work will be presented by Dr Kurt Kamrud, director of discovery research at AlphaVax and the Principal Investigator on both grants, at the XVII International Poxvirus and Iridovirus.